Results 11 to 20 of about 206,382 (334)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation

European Heart Journal, Supplement, 2022
Atrial fibrillation (AF) is associated with an increased risk of stroke, which can be prevented by the use of oral anticoagulation. Although non-vitamin K antagonist oral anticoagulants (NOACs) have become the first choice for stroke prevention in the ...
J. Farinha, I. Jones, G. Lip
semanticscholar   +1 more source

The Relationship Among Intestinal Bacteria, Vitamin K and Response of Vitamin K Antagonist: A Review of Evidence and Potential Mechanism

Frontiers in Medicine, 2022
The vitamin K antagonist is a commonly prescribed effective oral anticoagulant with a narrow therapeutic range, and the dose requirements for different patients varied greatly.
Han Yan, Yi Chen, Hong Zhu, Weihua Huang, Xin Cai, Dan Li, Yahui Lv, Si-Zhao, Honghao Zhou, Fan Luo, Wei Zhang, Xi Li   +11 more
semanticscholar   +1 more source

Percutaneous Left Atrial Appendage Occlusion in Comparison to Non‐Vitamin K Antagonist Oral Anticoagulant Among Patients With Atrial Fibrillation

Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2022
Background This study aimed to compare percutaneous left atrial appendage occlusion (LAAO) with non‐vitamin K antagonist oral anticoagulants among patients with atrial fibrillation. Methods and Results Using a US administrative database, 562 850 patients
P. Noseworthy, Holly K. Van Houten, H. Krumholz, D. Kent, N. Abraham, J. Graff‐Radford, M. Alkhouli, H. Henk, N. Shah, B. Gersh, P. Friedman, D. Holmes, Xiaoxi Yao   +12 more
semanticscholar   +1 more source

Non-vitamin K antagonist oral anticoagulants in patients with valvular heart disease

European Heart Journal, Supplement, 2022
The non-vitamin K antagonist oral anticoagulants (NOACs) dabigatran, rivaroxaban, apixaban, and edoxaban have transformed the management of atrial fibrillation (AF), but are only approved by regulatory authorities for stroke prophylaxis in patients with ...
Alexander C. Fanaroff, A. Vora, R. Lopes
semanticscholar   +1 more source

Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients

Stroke, 2021
Supplemental Digital Content is available in the text. Background and Purpose: Several observational studies have compared the effect of the non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation.
Wengen Zhu, Zi Ye, Shilan Chen, Dexi Wu, Jiangui He, Yugang Dong, G. Lip, Chen Liu   +7 more
semanticscholar   +1 more source

Urgent reversal of vitamin K antagonists [PDF]

BMJ, 2018
### What you need to know A 78 year old man is brought to the emergency department after collapsing. He is drowsy with signs of a left hemiparesis. Computed tomography of the brain shows an intracranial bleed. He has a history of atrial fibrillation, and he has been taking warfarin (INR target 2-3) for several years.
Beverley J, Hunt, Marcel, Levi
openaire   +5 more sources

Influence of vitamin K antagonist treatment on activated partial thromboplastin time [PDF]

, 2015
A
Devreese, Katrien, MULLIEZ, SYLVIE, Van den Bogaert, Julie   +2 more
core   +2 more sources

Comparison Between Non–vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism

JAMA Network Open, 2021
This cohort study compares the risks of venous thromboembolism (VTE) recurrence in patients receiving non–vitamin K antagonist oral anticoagulants (NOACs) vs low-molecular-weight heparin in Asian individuals with cancer.
Dong-Yi Chen, Chi-Nan Tseng, M. Hsieh, Wen-Ching Lan, C. Chuang, S. Pang, Shao‐Wei Chen, Tien‐Hsing Chen, Shang-Hung Chang, I. Hsieh, P. Chu, M. Wen, Jen‐Shi Chen, J. Chang, L. See, Wen-Kuan Huang   +15 more
semanticscholar   +1 more source

Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries

Europace, 2021
Aims To assess persistence and adherence to non-vitamin K antagonist oral anticoagulant (NOAC) treatment in patients with atrial fibrillation (AF) in five Western European healthcare settings.
J. Komen, A. Pottegård, A. Mantel‐Teeuwisse, T. Forslund, P. Hjemdahl, B. Wettermark, M. Hellfritzsch, J. Hallas, M. Olesen, M. Bennie, T. Mueller, A. Voss, T. Schink, U. Haug, Bianca Kollhorst, Ø. Karlstad, L. Kjerpeseth, O. Klungel   +17 more
semanticscholar   +1 more source

Antithrombotic therapy with rivaroxaban in five patients with paroxysmal nocturnal haemoglobinuria and thrombotic events [PDF]

, 2018
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivaroxaban an factor Xa inhibitor.
Cafolla, Arturo, Chiarotti, Flavia, Dragoni, Francesco, Iori, Anna Paola, La Rocca, Ursula   +4 more
core   +1 more source